Last reviewed · How we verify

ONEXTON Topical Gel

Derm Research, PLLC · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

ONEXTON Topical Gel is a Small molecule drug developed by Derm Research, PLLC. It is currently FDA-approved.

ONEXTON Topical Gel is a medication used to treat Acne Vulgaris and Acne, containing a combination of clindamycin 1% and benzoyl peroxide 3%. The exact mechanism of action of ONEXTON Topical Gel is unknown.

At a glance

Generic nameONEXTON Topical Gel
SponsorDerm Research, PLLC
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ONEXTON Topical Gel

What is ONEXTON Topical Gel?

ONEXTON Topical Gel is a Small molecule drug developed by Derm Research, PLLC.

Who makes ONEXTON Topical Gel?

ONEXTON Topical Gel is developed and marketed by Derm Research, PLLC (see full Derm Research, PLLC pipeline at /company/derm-research-pllc).

What development phase is ONEXTON Topical Gel in?

ONEXTON Topical Gel is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing